Pharmability originated from a pivotal scientific discovery made at the Karolinska Institutet, where Professor Anna-Lena Spetz uncovered the unique immunomodulatory potential of a single-stranded oligonucleotide, now known as TIR-01.

Unlike conventional therapies that broadly suppress the immune system, TIR-01 demonstrated the ability to modulate immune responses with precision, laying the groundwork for a new class of treatments for autoimmune and inflammatory diseases. This novel mechanism of action opened the door to developing safer and more targeted therapies, an approach that has become central to TIRmed's mission.

Since its founding in 2018, the company has made significant strides, advancing from academic research into preclinical and early-stage clinical development. Backed by a syndicate of leading life science investors, TIRmed is now well-positioned to bring its first product candidate, TIR-C, toward clinical validation. Our vision remains focused: to develop innovative therapies that address the unmet needs of patients while redefining the treatment landscape for immune-mediated conditions.

Pharmability

Org chart

Teams

Offices